Receptor gene messenger RNA expression in metastatic lesions of prostate cancer

Journal of Urology

Volumn 168, Issue 3, 2002, Pages 1212-1214

  Straub, Bernd ^a   Müller, Markus ^a   Krause, Hans ^a   Schrader, Mark ^a   Goessl, Carsten ^a   Miller, Kurt ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Gene expression; Lymphatic metastasis; Prostate; Prostatic neoplasms; Receptors, LHRH

Indexed keywords

BETA ACTIN; GONADORELIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECEPTOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0036718476     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)64627-7     Document Type: Article

References (25)

1. Cancer statistics, 1998
2. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: Association with progression-free survival, pain end points, and survival
3. Endocrine therapy of prostate cancer
4. Effects of LHRH-analogues on mitogenic signal transduction in cancer cells
5. Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord
6. Peptide analogs in the therapy of prostate cancer
7. Expression of mRNA for luteinizing hormone-releasing hormone receptors and epidermal growth factor receptors in human cancer cell lines
8. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II
9. Gonadotropin-releasing hormone receptor expression in the human prostate
10. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers
11. Increased incidence of luteinizing hormone-releasing hormone receptor gene messenger RNA expression in hormone-refractory human prostate cancers
12. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: Evidence for an autocrine-inhibitory LHRH loop
13. Cloning, sequencing, and expression of human gonadotropin releasing hormone (GnRH) receptor
14. Luteinizing hormone releasing hormone-RNase A conjugates specifically inhibit the proliferation of LHRH-receptor-positive human prostate and breast tumor cells
15. Expression of gonadotropin-releasing hormone (GnRH) and GnRH receptor mRNA in prostate cancer cells and effect of GnRH on the proliferation of prostate cancer cells
16. The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary
17. Signal transduction of GnRH receptor in the reproductive tract tumor
18. Effects of gonadotropin-releasing hormone analogues on ovarian epithelial tumors
19. Expression of gonadotropin-releasing hormone receptor mRNA in the rat ventral prostate and dunning R3327 PAP adenocarcinoma before and after castration
20. Receptors for gonadotropin releasing hormone are present in rat oocytes
21. Localization of receptors for luteinizing hormone-releasing hormone in pancreatic and mammary cancer cells
22. Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP
23. Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145
24. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice
25. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer